The creation of valuable new therapies is driven by innovative approaches to drug discovery and development. These approaches have the potential to dramatically shorten drug development timelines, significantly lower costs and decrease development risk.
The recent dearth of successful drug programs has made the private funding environment difficult. To stand out from the crowded field of startups, a company must know the investors, what type of companies and products investors are interested in and the type of scientific data that captures an investors attention. Combined with a global investor network, Culver provides an unparalleled advantage for represented companies in an uncertain capital market.
